Supply and Distribution Constraints This sudden increased demand for GLP-1s eventually led to supply shortages starting in March 2022, with a key contributing factor being the underlying difficulty of manufacturing peptide-based drugs
Studies indicate that SGLT2i modulate the activity of the myocardial-specific sodium-hydrogen exchanger 1 (NHE1), thereby improving mitochondrial respiratory function, maintaining myocardial Ca homeostasis, and delaying the decline in contractile function [113,114,115]
Clinical trials show Wegovy achieves average weight loss of 15-22% of body weight over 68 weeks in people who maintain lifestyle changes
Individuals with certain health conditions, such as kidney disease, heart conditions, or high blood pressure, should consult a healthcare provider before treatment
Hui H, Farilla L, Merkel P, Perfetti R (2002) The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects
79 The promising benefits observed in major cardiovascular trials have sparked interest in their potential application for HF, particularly in patients with comorbid T2D or metabolic syndrome
